Skip to main content

What the FDA labels say about taking them together

Chlorambucil and lenalidomide

Lenalidomide's FDA label of March 24, 2023 names chlorambucil in its warnings and precautions section; the chlorambucil label PlainMeds reads does not name lenalidomide. The lenalidomide label: “… REVLIMID therapy increased the risk of death as compared to single agent chlorambucil.”

Check it at the source: the chlorambucil FDA label on DailyMed (effective January 8, 2025, Waylis Therapeutics LLC); the lenalidomide FDA label on DailyMed (effective March 24, 2023, Celgene Corporation).

What does the chlorambucil label say about lenalidomide?

Chlorambucil's label (effective January 8, 2025) does not name lenalidomide in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (LEUKERAN), Waylis Therapeutics LLC, effective January 8, 2025 (SPL set 58a3c995-5ad6-465d-8437-5970c9088213), via openFDA; the full label on DailyMed

What does the lenalidomide label say about chlorambucil?

Lenalidomide label, warnings and precautions

Mortality in Patients with CLL In a prospective randomized (1:1) clinical trial in the first line treatment of patients with chronic lymphocytic leukemia, single agent REVLIMID therapy increased the risk of death as compared to single agent chlorambucil.

Source: FDA drug label (Revlimid), NDA021880 (Bristol Myers Squibb), as published by Celgene Corporation, effective March 24, 2023 (SPL set 5fa97bf5-28a2-48f1-8955-f56012d296be), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Chlorambucil generic labelers
18Lenalidomide generic labelers
ChlorambucilLenalidomide
Labeled forLeukemia, lymphoma and myelomaLeukemia, lymphoma and myeloma, Anemia
Boxed warningYesYes
Pharmacy cost (NADAC)n/an/a
Shortage nowNo current entryNo current entry

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?